Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 14, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses Amylyx’s therapy that was recently approved by the FDA, and what it means for the amyotrophic lateral sclerosis community and the global healthcare industry.
In this NeurologyLive® Peer Exchange series, an expert cardiologist, C. Michael Gibson, MD, leads a discussion with sleep specialist Nathaniel F. Watson, MD, and pulmonologist Ashgan Elshinawy, DO, who share insights on the awareness and treatment of sleep disorders, including insomnia, that co-occur with other health conditions.
In the latest edition of our in-depth Q&A series, the division chief of stroke and vascular neurology at Duke Health discussed how clinicians have typically treated poststroke motor symptoms and how technology is expanding these capabilities.
A study from Chao Quan, MD, et al showed that annualized relapse rates were elevated compared with the prepregnancy period, especially during the initial 3 months after delivery, whereas EDSS scores worsened during pregnancy and the postpartum period.
Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.